United Therapeutics Corporation (UTHR)

NMS – Real Time Price. Currency in USD

581.74

+11.86 (2.08%)

At close: May 12, 2026, 4:00 PM EDT

584.82

+3.08 (0.53%)

After-hours: May 12, 2026, 7:13 PM EDT

07.05.2026

UTHR Q1 Earnings Miss Estimates, Shares Jump on Strong Outlook

United Therapeutics shares rise after Q1 earnings miss estimates as investors focus on Tyvaso IPF data and ralinepag's blockbuster potential.

06.05.2026

United Therapeutics Corporation (UTHR) Q1 2026 Earnings Call Transcript

06.05.2026

United Therapeutics (UTHR) Misses Q1 Earnings and Revenue Estimates

United Therapeutics (UTHR) came out with quarterly earnings of $5.82 per share, missing the Zacks Consensus Estimate of $6.73 per share. This compares to earnings of $6.63 per share a year ago.

06.05.2026

United Therapeutics Corporation Reports First Quarter 2026 Financial Results

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2026. Total revenues in the first quarter of 2026 decreased by two percent year-over-year to $781.5 million, compared to $794.4 million in the first quarter of 2025. “In the first quarter of 2026, we extended our run of clinical success, with positive results from both our ADVANCE O.

05.05.2026

Ahead of United Therapeutics (UTHR) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Evaluate the expected performance of United Therapeutics (UTHR) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

04.05.2026

Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?

United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

30.04.2026

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the First Trust NYSE Arca Biotechnology ETF (FBT), a passively managed exchange traded fund launched on June 19, 2006.

Videos

No Data

There is no data to display

Press releases

06.05.2026

United Therapeutics Corporation Reports First Quarter 2026 Financial Results

29.04.2026

United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the term for Professor Raymond Dwek, C.B.E., F.R.S., as a member of the Board of Directors will expire at the 2026 Annual Meeting of Shareholders, scheduled for June 26, 2026. Prof. Dwek, who is widely recognized for his pioneering work at Oxford University in the field of glycobiology, joined the United Therapeutics Board in 2002.

20.04.2026

United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that 11 new data presentations across its commercial and development portfolio will be presented at the International Society for Heart and Lung Transplantation (ISHLT) 46th Annual Meeting and Scientific Sessions taking place April 22-25, 2026, in Toronto, Canada. "The data from ARTISAN and PHINDER suggest that earlier detection and in.

08.04.2026

United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to the company's investigational miroliverELAP®, an external liver assist product. Developed by Miromatrix Medical Inc., a wholly owned subsidiary of United Therapeutics, miroliverELAP consists of an external blood cir.

United Therapeutics Corporation (UTHR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

United Therapeutics Corporation (UTHR)

UTHR Q1 Earnings Miss Estimates, Shares Jump on Strong Outlook

United Therapeutics Corporation (UTHR) Q1 2026 Earnings Call Transcript

United Therapeutics (UTHR) Misses Q1 Earnings and Revenue Estimates

United Therapeutics Corporation Reports First Quarter 2026 Financial Results

Ahead of United Therapeutics (UTHR) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

Videos

No Data

Press releases

United Therapeutics Corporation Reports First Quarter 2026 Financial Results

United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors

United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026

United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure

UTHR Q1 Earnings Miss Estimates, Shares Jump on Strong Outlook

United Therapeutics Corporation (UTHR) Q1 2026 Earnings Call Transcript

United Therapeutics (UTHR) Misses Q1 Earnings and Revenue Estimates

United Therapeutics Corporation Reports First Quarter 2026 Financial Results

Ahead of United Therapeutics (UTHR) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

Videos

No Data

Press releases

United Therapeutics Corporation Reports First Quarter 2026 Financial Results

United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors

United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026

United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure

Search stocks

United Therapeutics Corporation (UTHR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

United Therapeutics Corporation (UTHR)

UTHR Q1 Earnings Miss Estimates, Shares Jump on Strong Outlook

United Therapeutics Corporation (UTHR) Q1 2026 Earnings Call Transcript

United Therapeutics (UTHR) Misses Q1 Earnings and Revenue Estimates

United Therapeutics Corporation Reports First Quarter 2026 Financial Results

Ahead of United Therapeutics (UTHR) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

Videos

No Data

Press releases

United Therapeutics Corporation Reports First Quarter 2026 Financial Results

United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors

United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026

United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure

UTHR Q1 Earnings Miss Estimates, Shares Jump on Strong Outlook

United Therapeutics Corporation (UTHR) Q1 2026 Earnings Call Transcript

United Therapeutics (UTHR) Misses Q1 Earnings and Revenue Estimates

United Therapeutics Corporation Reports First Quarter 2026 Financial Results

Ahead of United Therapeutics (UTHR) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

Videos

No Data

Press releases

United Therapeutics Corporation Reports First Quarter 2026 Financial Results

United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors

United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026

United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure